• Oct 26, 2026

  $286.74+0.39%

• Oct 23, 2026

  $285.64+0.16%

  AbbVie closed up 0.16% while comparable pharmaceutical companies fell 1.31% on average, with 5 of 6 declining [1]. The company's small gain was therefore not shared by its peer group [1].

  • 1Peer group

• Oct 22, 2026

  $285.19+0.14%

  AbbVie rose 0.14% while comparable pharmaceutical companies gained 1.80% on average, with 5 of 6 higher [2]. AbbVie therefore lagged the cohort's advance. Seeking Alpha reported positive late-stage results for lutikizumab in hidradenitis suppurativa [1].

  • 1Seeking Alpha
  • 2Peer group

• Oct 21, 2026

  $284.80-1.48%

• Oct 20, 2026

  $289.08+2.26%

  Comparable pharmaceutical companies rose 2.03% on average, with 5 of 6 higher, so the stock's 2.26% gain came alongside a broadly shared sector advance [2]. Seeking Alpha also reported that Alvotech won FDA approval for a new manufacturing process for its Humira biosimilar [1].

  • 1Seeking Alpha
  • 2Peer group

• Oct 19, 2026

  $282.68-0.96%

• Oct 16, 2026

  $285.42+0.71%

Closing prices for ABBV. Summaries describe past sessions only and are not advice, a forecast or a recommendation.

Headlines are published by third parties and linked as reported. Amaltash does not endorse or verify them.